Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine for chronic fatigue syndrome in psychiatric clinic patients in Shiraz
IRCT20250428065515N1Phase 2Completed
- Sponsor
- Islamic Azad University, Kazerun Branch
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisdexamfetamine in myalgic encephalomyelitis (ME), sponsored by Islamic Azad University, Kazerun Branch. Primary endpoint: Change in chronic fatigue syndrome symptom severity. Started Aug 2025; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on IRCT20250428065515N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250428065515N1.